SRTS
Neutral signalScored 2026-09-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Sensus Healthcare, Inc.
- Nom
- Sensus Healthcare, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $48.6M
- Employés
- 60
- PDG
- Joseph C. Sardano
- Site web
- https://www.sensushealthcare.com
- Marché
- BDMDCTSOICCMIPSCKPTIMDAI
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 171 171 titres (~563 538,30 $ US)
- Insiders
- Sachetta EricSardano Joseph C
- Total bought
-
$563,538
Avg buy (VWAP, 90d window) $3.29 vs last close $2.99 (-9.2%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-31
- Liquidity
- Illiquid $74,450/day · 20d vol
- Last synced
-
2026-09-30 21:10:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-31 | Sachetta Eric | Buy · P | 27,304 | $3.54 | $96,602 | Form 4 |
| 2026-08-28 | Sachetta Eric | Buy · P | 37,537 | $3.44 | $129,015 | Form 4 |
| 2026-08-27 | Sachetta Eric | Buy · P | 10,925 | $3.18 | $34,752 | Form 4 |
| 2026-08-26 | Sachetta Eric | Buy · P | 9,708 | $3.29 | $31,930 | Form 4 |
| 2026-08-24 | Sachetta Eric | Buy · P | 34,697 | $3.25 | $112,904 | Form 4 |
| 2026-08-21 | Sachetta Eric | Buy · P | 7,000 | $3.25 | $22,778 | Form 4 |
| 2026-08-20 | Sachetta Eric | Buy · P | 24,000 | $3.13 | $75,072 | Form 4 |
| 2026-08-20 | Sardano Joseph C | Buy · P | 20,000 | $3.02 | $60,486 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
SRTS presents a deeply conflicted profile: while insider cluster buys (~$563K) signal some conviction from management, the fundamental deterioration is severe, with a collapse in revenue (from $7.3M to $2.3M), negative…
The first sentence of the analysis written for SRTS on 2026-09-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 9.72 · operating margin -38% — readings disagree
Suggested stop 2.92, nearest stored support minus 0.5 ATR(2.4% under the last close). Reward/risk to the next stored resistance is 0.94. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 43.2% | 58.4% | 57.6% | 66.5% | 62.8% | |
| Ebit Margin | -35.0% | 21.6% | 2.7% | 62.9% | 15.2% | |
| Ebitda Margin | -33.6% | 22.6% | 4.6% | 64.0% | 17.5% | |
| Operating Profit Margin | -37.5% | 19.4% | -1.6% | 33.3% | 15.2% | |
| Pretax Profit Margin | -35.0% | 21.6% | 2.7% | 62.9% | 15.2% | |
| Continuous Operations Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Net Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Bottom Line Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Current Ratio | 9.719 | 9.641 | 11.759 | 6.917 | 5.240 | |
| Quick Ratio | 6.635 | 7.925 | 8.943 | 6.462 | 4.945 | |
| Solvency Ratio | -1.484 | 1.117 | 0.194 | 2.856 | 0.760 | |
| Cash Ratio | 4.677 | 3.748 | 5.496 | 3.316 | 2.435 | |
| Price To Earnings Ratio | -8.468 | 16.878 | 79.195 | 5.048 | 28.880 | |
| Price To Earnings Growth Ratio | 0.039 | 0.013 | -0.808 | 0.010 | -0.181 | |
| Forward Price To Earnings Growth Ratio | 0.039 | 0.013 | -0.808 | 0.010 | -0.181 | |
| Price To Earnings Diluted Ratio | -8.468 | 16.878 | 79.195 | 5.082 | 28.880 | |
| Price To Earnings Diluted Growth Ratio | 0.039 | 0.013 | -0.808 | 0.011 | -0.181 | |
| Price To Book Ratio | 1.351 | 2.022 | 0.786 | 2.544 | 4.573 | |
| Price To Sales Ratio | 2.365 | 2.700 | 1.572 | 2.746 | 4.399 | |
| Price To Free Cash Flow Ratio | 195.727 | -101.971 | -16.163 | -77.841 | -287.337 | |
| Price To Operating Cash Flow Ratio | 123.070 | -135.838 | -17.889 | -86.607 | -415.936 | |
| Debt To Assets Ratio | 0.013 | 0.010 | 0.015 | 0.018 | 0.007 | |
| Debt To Equity Ratio | 0.014 | 0.011 | 0.016 | 0.021 | 0.009 | |
| Debt To Capital Ratio | 0.014 | 0.011 | 0.016 | 0.021 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.004 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.103 | 1.114 | 1.100 | 1.180 | 1.239 | |
| Working Capital Turnover Ratio | 0.597 | 0.869 | 0.537 | 1.258 | 1.186 | |
| Operating Cash Flow Ratio | 0.112 | -0.141 | -0.509 | -0.183 | -0.048 | |
| Operating Cash Flow Sales Ratio | 0.019 | -0.020 | -0.088 | -0.032 | -0.011 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.629 | 1.332 | 1.107 | 1.113 | 1.448 | |
| Debt Service Coverage Ratio | -27.989 | 0.000 | 0.000 | 12,377.500 | 91.038 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 7,415.500 | 4,120.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.015 | 0.000 | 0.000 | 0.000 | -5.608 | |
| Operating Cash Flow Coverage Ratio | 0.776 | -1.380 | -2.739 | -1.384 | -1.271 | |
| Capital Expenditure Coverage Ratio | 2.694 | -3.011 | -9.367 | -8.881 | -2.234 | |
| Dividend Paid And Capex Coverage Ratio | 2.694 | -3.011 | -9.367 | -8.881 | -2.234 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.717 | 9.671 | 14.382 | 3.431 | 22.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 43.2% | ▼-15.3% | ▼-14.5% |
| Ebit Margin | -35.0% | ▼-56.6% | ▼-48.5% |
| Ebitda Margin | -33.6% | ▼-56.2% | ▼-48.6% |
| Operating Profit Margin | -37.5% | ▼-56.9% | ▼-43.3% |
| Pretax Profit Margin | -35.0% | ▼-56.6% | ▼-48.5% |
| Continuous Operations Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Net Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Bottom Line Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Current Ratio | 9.719 | ▲0.078 | ▲1.064 |
| Quick Ratio | 6.635 | ▼-1.291 | ▼-0.347 |
| Solvency Ratio | -1.484 | ▼-2.601 | ▼-2.173 |
| Cash Ratio | 4.677 | ▲0.929 | ▲0.743 |
| Price To Earnings Ratio | -8.468 | ▼-25.346 | ▼-32.775 |
| Price To Earnings Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Forward Price To Earnings Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Price To Earnings Diluted Ratio | -8.468 | ▼-25.346 | ▼-32.781 |
| Price To Earnings Diluted Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Price To Book Ratio | 1.351 | ▼-0.671 | ▼-0.904 |
| Price To Sales Ratio | 2.365 | ▼-0.336 | ▼-0.392 |
| Price To Free Cash Flow Ratio | 195.726 | ▲297.697 | ▲253.244 |
| Price To Operating Cash Flow Ratio | 123.070 | ▲258.909 | ▲229.710 |
| Debt To Assets Ratio | 0.013 | ▲0.003 | ▲0.000 |
| Debt To Equity Ratio | 0.014 | ▲0.003 | -0.000 |
| Debt To Capital Ratio | 0.014 | ▲0.003 | -0.000 |
| Long Term Debt To Capital Ratio | 0.004 | ▲0.004 | ▲0.004 |
| Financial Leverage Ratio | 1.103 | ▼-0.011 | ▼-0.044 |
| Working Capital Turnover Ratio | 0.597 | ▼-0.272 | ▼-0.292 |
| Operating Cash Flow Ratio | 0.112 | ▲0.253 | ▲0.266 |
| Operating Cash Flow Sales Ratio | 0.019 | ▲0.039 | ▲0.045 |
| Free Cash Flow Operating Cash Flow Ratio | 0.629 | ▼-0.703 | ▼-0.497 |
| Debt Service Coverage Ratio | -27.988 | ▼-27.988 | ▼-2516.099 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-2307.100 |
| Short Term Operating Cash Flow Coverage Ratio | 2.015 | ▲2.015 | ▲2.734 |
| Operating Cash Flow Coverage Ratio | 0.776 | ▲2.157 | ▲1.976 |
| Capital Expenditure Coverage Ratio | 2.694 | ▲5.705 | ▲6.854 |
| Dividend Paid And Capex Coverage Ratio | 2.694 | ▲5.705 | ▲6.854 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.717 | ▼-14.388 | ▼-13.692 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $65.0M | $112.9M | $38.4M | $122.3M | $119.0M | |
| Enterprise value | $43.6M | $91.4M | $16.0M | $97.8M | $104.7M | |
| EV / Sales | 1.59x | 2.19x | 0.66x | 2.20x | 3.87x | |
| EV / Op. cash flow | 82.53x | -110.02x | -7.46x | -69.26x | -365.96x | |
| EV / Free cash flow | 131.26x | -82.59x | -6.74x | -62.25x | -252.81x | |
| EV / EBITDA | -4.72x | 9.67x | 14.38x | 3.43x | 22.11x | |
| Net debt / EBITDA | 2.32x | -2.27x | -20.09x | -0.86x | -3.02x | |
| Current ratio | 9.72x | 9.64x | 11.76x | 6.92x | 5.24x | |
| Income quality | -0.07x | -0.12x | -4.42x | -0.06x | -0.07x | |
| Graham number | — | $6 | $1 | $10 | $3 | |
| Graham net-net | $2 | $2 | $2 | $2 | $1 | |
| Tax burden | 80.2% | 73.7% | 74.4% | 86.6% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $41.2M | $50.9M | $45.3M | $45.5M | $25.3M | |
| Invested capital | $43.6M | $53.4M | $46.6M | $46.8M | $26.2M | |
| Return on assets | -14.6% | 10.7% | 0.9% | 42.7% | 12.8% | |
| Operating ROA | -17.9% | 14.0% | -0.7% | 33.3% | 13.7% | |
| Return on tangible assets | -14.6% | 10.7% | 0.9% | 42.8% | 12.8% | |
| Return on equity | -16.0% | 11.9% | 1.0% | 50.4% | 15.8% | |
| Return on invested capital | -17.0% | 10.6% | -0.6% | 26.1% | 15.5% | |
| Return on capital employed | -21.3% | 14.4% | -0.8% | 30.2% | 15.7% | |
| Earnings yield | -11.9% | 5.9% | 1.3% | 19.8% | 3.5% | |
| Free cash flow yield | 0.5% | -1.0% | -6.2% | -1.3% | -0.3% | |
| Capex / Op. cash flow | 37.1% | -33.2% | -10.7% | -11.3% | -44.8% | |
| Capex / Depreciation | 31.3% | 63.9% | 49.7% | 31.2% | 20.9% | |
| Capex / Sales | 0.7% | 0.7% | 0.9% | 0.4% | 0.5% | |
| SG&A / Sales | 52.4% | 29.0% | 44.1% | 25.5% | 34.9% | |
| R&D / Sales | 28.3% | 10.1% | 15.1% | 7.8% | 12.7% | |
| Stock comp / Sales | 1.1% | 0.8% | 1.3% | 0.4% | 1.5% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.1% | 0.5% | |
| Days sales outstanding | 80d | 172d | 159d | 142d | 164d | |
| Days payables outstanding | 78d | 101d | 99d | 135d | 147d | |
| Operating cycle | 421d | 384d | 578d | 228d | 228d | |
| Cash conversion cycle | 342d | 283d | 479d | 92d | 80d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 Sensus Healthcare Q2 Earnings Call Highlights Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
- 2026-08-13 Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
- 2026-08-13 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un.
- 2026-07-30 Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026 BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc.